Showing results (1-10 of 75) with videos related to
Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
How to develop a successful cancer drug--molecules to medicines or targets to treatments?David R NewellClinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Pharmacologic biomarkers in the development of stratified cancer medicineWilliam Douglas Figg, David R NewellCancer Chemotherapy and Pharmacology|June 2, 2011
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombinationMichele Tavecchio, Joanne M Munck, Celine Cano, et al.Oncotarget|January 27, 2018
Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2Britta Vormoor, Yvonne T Schlosser, Helen Blair, et al.Cancer Letters|April 7, 2015
SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastomaLaura Evans, Lindi Chen, Giorgio Milazzo, et al.Oncotarget|April 7, 2015
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastomaLindi Chen, Raphaël F Rousseau, Steven A Middleton, et al.Cancer Chemotherapy and Pharmacology|May 25, 2006
An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexedClaire L Graham-Cole, Huw D Thomas, Gordon A Taylor, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemiaAlan V Boddy, Julieann Sludden, Melanie J Griffin, et al.European Journal of Cancer (Oxford, England : 1990)|January 29, 2016
Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependentEmma J Haagensen, Huw D Thomas, Clare Mudd, et al.Molecular Cancer Therapeutics|March 21, 2013
Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancerMichael A Batey, Yan Zhao, Suzanne Kyle, et al.Pageof 8